Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -12.56% | 15.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.56% | 15.27% | |||
| Cost of Revenue | -11.00% | 11.59% | |||
| Gross Profit | -13.60% | 17.89% | |||
| SG&A Expenses | 28.45% | -11.09% | |||
| Depreciation & Amortization | -3.53% | -0.58% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.29% | 0.31% | |||
| Operating Income | -128.24% | 1,257.14% | |||
| Income Before Tax | -3.21% | -182.54% | |||
| Income Tax Expenses | 132.77% | -468.04% | |||
| Earnings from Continuing Operations | -20.27% | -131.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.27% | -131.28% | |||
| EBIT | -128.24% | 1,257.14% | |||
| EBITDA | -91.21% | 197.96% | |||
| EPS Basic | -19.93% | -131.02% | |||
| Normalized Basic EPS | -2.53% | -174.85% | |||
| EPS Diluted | -20.63% | -112.77% | |||
| Normalized Diluted EPS | -2.53% | -174.85% | |||
| Average Basic Shares Outstanding | 0.29% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.29% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||